Best Gene Therapy CDMOs in Asia

· updated as new inspection, certificate, and trial data enters the platform

Gene Therapy manufacturers on CDMO Signal: 11 listed with manufacturing sites in Asia, 10 with a Signal Score. Together they have 14 FDA inspections on file (including 9 NAI, 5 VAI and 0 OAI) and 33 EMA/MHRA GMP certificates. Fewer than three are fully evidenced (all four score pillars and at least one ClinicalTrials.gov match), so this page does not name a top three. Signal Score is computed from FDA inspection records, EMA EudraGMDP and MHRA GMP certificates, and ClinicalTrials.gov. CDMOs cannot pay to change it. Updated 2026-11-20. Methodology.

Gene Therapy CDMOs in Asia with the most regulatory evidence on file

AGC Biologics
79.9
Longmont, CO · Milan, IT · Copenhagen, DK · Chiba, JP
4 FDA inspections · 27 EMA/MHRA GMP certs
Last FDA inspection: 2026-05-29 · NAI
See the evidence →
Pharmaron
86.9
San Diego, CA · Shaoxing, China, Liverpool, UK, Ningbo China
5 FDA inspections · 1 EMA/MHRA GMP cert
Last FDA inspection: 2026-08-14 · NAI
See the evidence →
WuXi Biologics
82.7
Shanghai, CN · Wuxi, CN
1 FDA inspection · 4 EMA/MHRA GMP certs
Last FDA inspection: 2026-07-03 · VAI
See the evidence →
Lotte Biologics
81.6
Incheon, KR · Syracuse, NY
2 FDA inspections · 0 EMA/MHRA GMP certs
Last FDA inspection: 2026-09-18 · NAI
See the evidence →
Ajinomoto Bio-Pharma Services
83.5
San Diego, CA · Osaka, JP
0 FDA inspections · 1 EMA/MHRA GMP cert
Last FDA inspection: None on file
See the evidence →
11
CDMOs tracked
10
Fully scored
6
With FDA records
14
FDA inspections
33
EMA/MHRA GMP certs

Gene therapy is delivered through viral vectors — AAV, lentiviral, and adenoviral being the three dominant platforms. AAV dominates in vivo systemic delivery (rare disease, ophthalmology, neurology); lentivirus is the workhorse for ex vivo cell engineering including CAR-T; adenoviral vectors remain relevant for vaccines and select gene therapy programs. Most gene therapy CDMOs specialize in one or two vector platforms, and platform experience is the first filter in any sponsor's shortlist.

The ranking below aggregates every CDMO tracked as a gene therapy manufacturer across these platforms. For platform-specific rankings, use the dedicated pages: <a href="/modality/aav">AAV CDMOs</a>, <a href="/modality/lentiviral">Lentiviral Vector CDMOs</a>, <a href="/modality/adenoviral">Adenoviral Vector CDMOs</a>. For sponsors evaluating end-to-end programs that combine vector manufacturing with downstream cell processing, the <a href="/modality/cell-and-gene-therapy">cell and gene therapy view</a> extends this list with cell therapy CDMOs.

FDA inspection outcomes across these CDMOs: 9 NAI (no action), 5 VAI (voluntary action), 0 OAI (official action). Leading inspection & GMP sites: Denmark (23), United States (9), Germany (4), China (3), Ireland (2).

Last updated 2026-11-20. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.

Ranked by Signal Score (0–100). Fully evidenced marks a CDMO scored on all four pillars with at least one confirmed clinical program. Partly scored and profile-only CDMOs follow the scored rows. How we score

Showing contract manufacturers only.

# CDMO Signal Score Quality FDA · GMP Last FDA inspection Capacity Programs
1
PB
San Diego, CA · Shaoxing, China, Liverpool, UK, Ningbo China
86.9 100.0 5 insp · 1 GMP 2026-08-14 · NAI Available —
2
AJ
San Diego, CA · Osaka, JP
83.5 100.0 0 insp · 1 GMP None on file — —
3
WB2
Shanghai, CN · Wuxi, CN
82.7 99.6 1 insp · 4 GMP 2026-07-03 · VAI — —
4
LB
Incheon, KR · Syracuse, NY
Hiring · 8 open roles
81.6 100.0 2 insp · 0 GMP 2026-09-18 · NAI — —
5
AG
Longmont, CO · Milan, IT · Copenhagen, DK · Chiba, JP
Hiring · 38 open roles
Fully evidenced
79.9 99.8 4 insp · 27 GMP 2026-05-29 · NAI Available 2 programs
6
GZ
Indianapolis, IN · Lexington, MA
Hiring · 26 open roles
78.1 100.0 1 insp · 0 GMP 2025-08-27 · NAI Available —
7
HX
Seoul, KR
Also makes its own products
59.0 — — None on file — —
8
TR
Kusatsu, Shiga Prefecture, Japan
57.9 — — None on file — 8 programs
9
UB
Shanghai, CN · Boston, MA
Hiring · 1 open role
56.5 — — None on file — —
—
Chongqing, China
Profiled — 1 insp · 0 GMP 2024-03-29 · NAI — —
How we score CDMOs →

What to evaluate in a Gene Therapy CDMO

Vector platform match
The first shortlist filter for any gene therapy program is vector platform. AAV for in vivo systemic; lentiviral for ex vivo cell engineering; adenoviral for vaccines and select high-expression programs. Filter by platform first, then compare within the platform.
Regulatory record on-platform
A CDMO with a strong FDA record on AAV manufacturing doesn't automatically de-risk lentiviral work — inspections are facility- and process-specific. Verify the inspection record on the exact platform and site your program will use.
Capacity match to phase
Early clinical AAV runs at 50-200L; commercial can reach 1000-2000L single-batch. Lentiviral commercial supply is a much narrower field. Confirm the CDMO's capacity headroom at your target phase before shortlisting.
Analytics maturity
Vector analytics — capsid ratio, titer, potency, RCL for lentivirus — drive lot release. A CDMO with qualified, established assays de-risks comparability and tech transfer.

Regulatory landscape across PMDA (Japan), NMPA (China), MFDS (South Korea)

Asian biopharma manufacturing spans multiple national regulators. PMDA (Japan) is generally regarded as one of the most stringent in Asia, with GMP requirements broadly aligned with FDA and EMA. NMPA (China) has substantially strengthened its GMP framework over the past decade, and Chinese CDMOs increasingly hold FDA and EMA certifications alongside NMPA registration. MFDS (South Korea) certification is standard for Korean CDMOs. For sponsors supplying US or EU markets, the qualifying signal for an Asian CDMO is typically FDA and EMA inspection history on the specific facility — which the Signal Score's Quality Compliance pillar captures directly.

Which Asian CDMOs cover FDA (US) and EMA/MHRA (Europe) regulatory geographies?

Asian CDMOs with US FDA and European EMA/MHRA inspection history are qualified to supply global markets; those without cross-jurisdictional inspection posture are typically limited to their home-market regulatory scope. The Signal Score's Quality Compliance pillar includes FDA + EMA + MHRA data directly, so Asian CDMOs with cross-jurisdictional certification typically rank higher on this pillar than home-market-only competitors. Sponsors evaluating an Asian CDMO for a US or EU program should cross-check with the US region ranking and Europe region ranking — CDMOs appearing across regions have demonstrated multi-jurisdictional posture.

Recent US regulatory events affecting Asian CDMO selection (WuXi 1260H, BioSecure Act considerations)

Asian CDMOs — particularly Chinese-headquartered players — are subject to US regulatory events that affect sponsor risk assessment. The US Department of Defense's 1260H list (which added WuXi AppTec in June 2026) and the BioSecure Act (proposed federal legislation restricting federally-funded research and Medicare/Medicaid drug programs from working with named Chinese biotech companies) are both active considerations. CDMO Signal's platform does not encode US political risk into the Signal Score directly — the composite reflects regulatory quality, operations, financial stability, and capacity signals. Sponsors weighing an Asian CDMO for a US-supplying program should evaluate US regulatory risk separately as a distinct decision layer alongside the Signal Score-based capability assessment.

Gene Therapy CDMOs — Frequently Asked Questions

How many Gene Therapy CDMOs have FDA inspection records?
CDMO Signal tracks 6 Gene Therapy CDMOs with FDA inspection records and 33 EMA/MHRA GMP certificates across the group.
What should I look for in a gene therapy CDMO?
Match the vector platform to your program first (AAV / lentiviral / adenoviral). Then verify the CDMO's on-platform inspection record, capacity at your target phase, analytics maturity for that vector type, and a clean FDA and EMA/MHRA record. The individual platform pages have platform-specific detail.
How many gene therapy CDMOs does CDMO Signal track?
The table on this page is the live list: the union of AAV, lentiviral, adenoviral, and generally-tagged gene therapy manufacturers. Each is scored independently on the standard four-pillar Signal Score. CDMOs cannot pay to change a score.
Compare side-by-side
See two CDMOs' scoring, inspection history, and clinical footprint next to each other.
Open comparison →
Run a sourcing search
Describe your program's requirements — Signal matches CDMOs against FDA, EMA/MHRA, ClinicalTrials.gov and capacity signals.
Search for a CDMO →
Save this Gene Therapy shortlist
Get an email when a CDMO on this list has a new FDA inspection, GMP certificate, or scoring change.
Related modalities
AAV / Gene Therapy CDMOs Lentiviral Vector CDMOs Adenoviral Vector CDMOs Cell Therapy CDMOs
Other Modalities
AAV CAR-T Lentiviral Cell Therapy mRNA/LNP Plasmid DNA Biologics Oligo/ASO Adenoviral Gene Editing Exosome Recombinant Proteins ADC Cell & Gene Therapy Viral Vector